Leap Therapeutics, Inc. (LPTX) P/E Ratio History
Insufficient DataValuation data unavailable. · Data 2025–2025
Loading P/E history...
P/E Ratio Analysis
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our LPTX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
LPTX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
LPTX P/E vs Peers
Crypto Treasury Companies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $298M | 21.2Lowest | - | +100% | |
| $9B | 21.3 | - | +1747%Best | |
| $362B | 148.2 | 6.98Best | +8% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
LPTX Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Dec 31 2025 | $1.16 | $0.07 | 16.6x | +0% |
Average P/E for displayed period: 16.6x
LPTX Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
1+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LPTX — Frequently Asked Questions
Quick answers to the most common questions about buying LPTX stock.
What is LPTX's P/E ratio?
Leap Therapeutics, Inc. (LPTX) trailing twelve-month P/E ratio is N/A, based on TTM diluted EPS of N/A. The 5-year average P/E is 16.6x and the historical range spans 16.6x to 16.6x.
Is LPTX stock overvalued or undervalued?
LPTX current P/E: N/A. 5-year average P/E: 16.6x. Percentile: N/A.
Is LPTX stock expensive?
LPTX is fairly valued relative to its own history. The current P/E of N/A is near the 5-year average of 16.6x (N/A percentile of historical range).
What is LPTX's historical P/E range?
Over the past 5 years, LPTX's P/E ratio has ranged from 16.6x to 16.6x, with a median of 16.6x and an average of 16.6x. The current P/E of N/A places the stock at the N/A percentile of this range. Full historical data spans 2025–2025.
How does LPTX's P/E compare to the S&P 500?
LPTX current P/E: N/A. S&P 500 median P/E: 21.8x.
How does LPTX's valuation compare to Financial Services peers?
Leap Therapeutics, Inc. P/E of N/A can be benchmarked against Financial Services peers in the comparison table on this page.
What is LPTX's PEG ratio?
LPTX PEG ratio is N/A. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is LPTX's earnings yield?
LPTX earnings yield is N/A, the inverse of its N/A P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.